Novo Nordisk rises after Pfizer ends development of weight-loss pill

ReutersApr 14, 2025 11:36 AM

Shares in Novo Nordisk NOVOb.CO rise about 4% after Pfizer PFE.N on Monday said it has discontinued development of experimental weight-loss pill danuglipron

Discontinuation comes after a trial patient experienced potential drug-induced liver injury which resolved after the medication was stopped

Nordnet analyst Per Hansen attributes the share gain to the Pfizer announcement, and says that weight loss market and data can move stock prices in early stages

"Pfizer dropping a project shows that not all projects that Novo Nordisk and Eli Lilly or new competitors work on end up succeeding," Hansen also notes

If gains hold, Novo tracks best day since February 21

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Recommended Articles

Trump Blockade of Strait of Hormuz Drives Oil Price Surge, Will This Be Another TACO?

TradingKey - On Sunday (April 13), Donald Trump announced that following the breakdown of U.S.-Iran negotiations, the U.S. Navy will implement a naval blockade on Iranian ports starting Monday.

Up 20% in Five Days, Over 50% This Year: Why Was Marvell Technology Tapped by Nvidia?

TradingKey - Since April 2026, Marvell Technology (MRVL) has demonstrated sustained stock price strength. On April 10, the shares closed at $128.49, up 7.14% for the day. The stock has seen a cumulative gain of nearly 20% over the past five trading days, with an overall increase of 29.72% in April.

Musk’s XChat Is Coming to App Store, Meta, Apple and Finance World Are Trembling

Elon Musk’s XChat, the Western equivalent of WeChat, is set to launch on the App Store, issuing a direct challenge to giants such as Meta, Apple, and PayPal.

Microsoft Launches Its Own AI Models and Ditches OpenAI Dependence - Is MSFT Stock a Buy at $370?

Microsoft at $370 is a 17%-revenue-growth, 47%-margin, $625-billion-backlog business trading at a multi-year low valuation, because the market is scared of macro noise. The AI model releases this week prove the moat is deepening, not narrowing.

Anthropic IPO 2026: What the Claude Mythos Release Delay Means for Investors and Stock Valuation

Anthropic has delayed the launch of its new AI model, Claude Mythos, projecting a responsible image but potentially weighing on its IPO process.

Featured Tools